The combination treatment inhibited the EGFR/JAK/STAT3 signaling pathway and reduced PD-L1 expression, concurrent with increased immune-mediated tumor cell death through the perforin/granzyme B pathway. The gene discussed is GZMB; the disease is neoplasm.